Prostate MR Imaging in 2011: Current Role in Staging and Surveillance; Nov. 28, 8:30am-10:00am

TriMed Staff | | Health Imaging | Diagnostic Imaging
A team of researchers will review the basics of prostate MR imaging, including the limitations of current therapeutic approaches; prostate cancer care guidelines; indications for prostate MR imaging and its role in diagnosis, management and biopsy.

When: Monday, Nov. 28, 8:30-10:00am
Where: S406B

Speaker information:
Peter L. Choyke, MD, chief senior clinician molecular imaging, National Cancer Institute, Bethesda, Md.
Masoom Haider, MD, clinician scientist, Ontario Institute for Cancer Research, Toronto
Neil M. Rofsky, MD, chief MRI, Beth Israel Deaconess Medical Center, Boston

TriMed Staff

Related Content

AI rules out abnormal findings on chest X-rays, significantly reducing workloads
Older adults among the walking wounded with incident TBI
Philips moves digital pathology to the cloud with AWS
PHOTO GALLERY: What does fetal medical imaging look like?
Speaker laments radiology’s major contribution to climate change
Radiologist accuracy takes a hit overnight, especially with advanced imaging exams

Around the web

Radiology Business
The biggest obstacles facing radiology business managers in 2025

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Cardiovascular Business
New cardiac prevention paradigm explored in TRANSFORM trial using AI and CCTA

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

Cardiovascular Business
Cardiology practices pay $17.7M to settle fraud allegations brought on by whistleblowers

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.